Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK3 | P27361 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 10/20 | 0.45 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.42 |
| ▸ | GRK2 | P25098 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6028850 | 0.79 | MAPK14 (0.48) | MAPK14MAPK11ROCK2GSK3BROCK1 | |
| SCHEMBL4336706 | 0.78 | MAPK14 (0.43) | MAPK14MAPK11ROCK2GSK3BROCK1 | |
| SCHEMBL6029537 | 0.77 | MAPK14 (0.42) | MAPK14MAPK11HDAC6ROCK2GSK3B | |
| SCHEMBL4331656 | 0.73 | MAPK14 (0.54) | MAPK14MAPK11KCNH2 | |
| SCHEMBL4336938 | 0.71 | MAPK14 (0.56) | MAPK3MAPK1MAPK14MAPK11KCNH2 | |
| SCHEMBL4340891 | 0.71 | MAPK14 (0.44) | MAPK14MAPK11ROCK2GSK3BROCK1 | |
| SCHEMBL4336948 | 0.70 | MAPK14 (0.47) | MAPK14MAPK11ROCK2GSK3BROCK1 | |
| SCHEMBL5256306 | 0.69 | MAPK14 (0.50) | MAPK14MAPK11KCNH2ROCK2GRK2 | |
| SCHEMBL6028826 | 0.69 | MAPK14 (0.43) | MAPK14MAPK11HDAC6ROCK2GSK3B | |
| SCHEMBL13785091 | 0.69 | MAPK14 (0.48) | MAPK14MAPK11KCNH2ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192164-A1 | Treating agent of inflammatory bowel disease | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-07-30 | — | — | US | claimed |
| EP-2044957-A1 | TREATMENT AGENT FOR INFLAMMATORY BOWEL DISEASE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-04-08 | — | — | EP | claimed |
| US-20090192164-A1 | Treating agent of inflammatory bowel disease | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-07-30 | — | — | US | disclosed |
| EP-2044957-A1 | TREATMENT AGENT FOR INFLAMMATORY BOWEL DISEASE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192164-A1 | Treating agent of inflammatory bowel disease | MAPK6, SLC10A2, MAP3K6 | MAPK3 20/4885MAPK1 25/4885MAPK14 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.